信必可都保联合BiPAP辅助治疗COPD合并Ⅱ型呼吸衰竭疗效观察

信必可都保联合BiPAP辅助治疗COPD合并Ⅱ型呼吸衰竭疗
效观察
王洪玉
【期刊名称】《淮海医药》
【年(卷),期】2017(035)003
【摘要】Objective:To observe the clinical effect of symbicort turbuhaler combined with noninvasive bilevel positive airway pressure
ventilation(BiPAP)in the adjuvant treatment of chronic obstructive pulmonary disease (COPD) complicated with type II respiratory
failure.Methods:76 patients with COPD complicated with type II respiratory failure admitted in our department were randomly divided into a treatment group and a control group, 38 cases in each.Respiratory conventional treatment and BiPAP noninvasive ventilation were employed in the control group, and on the basis of the former, symbicort turbuhaler (160μg /4.5μg) was applied to the patients in the treatment group for 14 days, one suction once and twice a day.Blood gas analysis after 72 hours and lung function after 14 days were compared to evaluate the curative effect.Results:The blood gas analysis indicators after noninvasive ventilation for 72 hours and lung function index after 14 days in the two groups improved(P<0.01),but the blood gas analysis indicators such as pH,PaO2, PaCO2 and the lung function index such as forced expiratory volume in 1 second to predicted rate (FEV1%),forced expiratory volume in
one second to forced vital capacity rate(FEV1/FVC)in the treatment group improved more significantly than in the control group (P<0.05 or
P<0.01).Conclusion:Symbicort turbuhaler combined with BiPAP noninvasive ventilation can alleviate the condition of patients with COPD complicated with type II respiratory failure and improve the blood gas analysis indicators and the lung function index.It is worth extending in clinical practice.%目的:探讨信必可都保联合无创双水平正压通气(BiPAP)辅助治疗慢性阻塞性肺疾病(COPD)合并Ⅱ型呼吸衰竭患者临床疗效.方法:选择同期收治的76例COPD合并Ⅱ型呼吸衰竭患者,将患者随机分为治疗组和对照组各38例,对照组给予呼吸内科常规治疗联合BiPAP通气,治疗组在此基础上予以信必可都保(160μg /4.5μg),每次1吸,每天2次,治疗14 d.将2组治疗72 h血气分析指标及治疗14 d后测肺功能指标进行对比,评价疗效.结果:无创通气72 h后血气指标及治疗14 d后肺功能指标均较前显著改善(P<0.01),但治疗组血气分析指标pH
值,PaO2,PaCO2,肺功能指标第1秒用力呼气量占预计值百分比(FEV1%)、第1秒用力呼气量占用力肺活量百分比(FEV1/FVC)较对照组改善更为明显(P<0.05).结论:信必可都保联合BiPAP可有效缓解 COPD合并Ⅱ型呼吸衰竭患者病情,有效改善其血气分析及肺功能指标.
【总页数】3页(P282-284)
【作者】王洪玉
【作者单位】天津市泰达医院呼吸科,300457
【正文语种】中文
【中图分类】R563.9
【相关文献】
1.参芪扶正注射液联合BiPAP无创通气及纳洛酮治疗COPD合并Ⅱ型呼吸衰竭疗效观察 [J], 王惠霞
2.BiPAP联合舒利迭对AECOPD合并Ⅱ型呼吸衰竭老年患者的疗效观察 [J], 童皖宁;卓安山;曹玉书;徐世林
3.BiPAP Vision无创呼吸机联合体位活动护理对重度COPD合并Ⅱ型呼吸衰竭的疗效观察 [J], 黄秀琴;陈瑞梅;赵秀秀;叶瑞海;上官宗校
4.舒利迭联合BiPAP辅助治疗老年COPD并Ⅱ型呼吸衰竭疗效观察 [J], 刘杰远;王艳春;贾光;焦付丰
5.自拟清肺化痰方联合无创通气、信必可都保治疗老年AECOPD伴呼吸衰竭的疗效研究 [J], 肖磊;马丽敏;刘美秀
因版权原因，仅展示原文概要，查看原文内容请购买。